Hassan G, Seno M. Blood and cancer: cancer stem cells as origin of hematopoietic cells in solid tumor microenvironments. Cells. 2020;9(5). https://doi.org/10.3390/cells9051293.

Newell LF, Cook RJ. Advances in acute myeloid leukemia BMJ. 2021;375:n2026. https://doi.org/10.1136/bmj.n2026.

Article  PubMed  Google Scholar 

Mo JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014;15(6):642–56. https://doi.org/10.15252/embr.201438638.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bishop MR, Maziarz RT, Waller EK, Jäger U, Westin JR, McGuirk JP, Fleury I, Holte H, Borchmann P, Del Corral C, et al. Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. Blood Adv. 2019;3(14):2230–6. https://doi.org/10.1182/bloodadvances.2019000151.

Article  CAS  PubMed  PubMed Central  Google Scholar 

June CH, Sadelain M. Chimeric Antigen receptor therapy. N Engl J Med. 2018;379(1):64–73. https://doi.org/10.1056/NEJMra1706169.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maus MV, Levine BL. Chimeric antigen receptor T-cell therapy for the community oncologist. Oncologist. 2016;21(5):608–17. https://doi.org/10.1634/theoncologist.2015-0421.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45–55. https://doi.org/10.1016/j.blre.2018.11.002.

Article  CAS  PubMed  Google Scholar 

Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, Li F, Xie D, Xiong X, Wang J, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia. J Hematol Oncol. 2022;15(1):88. https://doi.org/10.1186/s13045-022-01308-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tabata R, Chi S, Yuda J, Minami Y. Emerging immunotherapy for acute myeloid leukemia. Int J Mol Sci 2021;22(4). https://doi.org/10.3390/ijms22041944.

Marofi F, Rahman HS, Al-Obaidi ZMJ, Jalil AT, Abdelbasset WK, Suksatan W, Dorofeev AE, Shomali N, Chartrand MS, Pathak Y, et al. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. Stem Cell Res Ther. 2021;12(1):465. https://doi.org/10.1186/s13287-021-02420-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sauer T, Parikh K, Sharma S, Omer B, Sedloev D, Chen Q, Angenendt L, Schliemann C, Schmitt M, Müller-Tidow C, et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021;138(4):318–30. https://doi.org/10.1182/blood.2020008221.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol. 2018;18(1):35–45. https://doi.org/10.1038/nri.2017.76.

Article  CAS  PubMed  Google Scholar 

• Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek MR, Vick B, Dede S, et al. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat Biotechnol. 2023. https://doi.org/10.1038/s41587-023-01684-0. An novel and systematic method (single-cell transcription) was used and reported to select adapt antigens of AML.

Hebbar N, Epperly R, Vaidya A, Thanekar U, Moore SE, Umeda M, Ma J, Patil SL, Langfitt D, Huang S, et al. CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells. Nat Commun. 2022;13(1):587. https://doi.org/10.1038/s41467-022-28243-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gumber D, Wang LD. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77:103941. https://doi.org/10.1016/j.ebiom.2022.103941.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trad R, Warda W, Alcazer V, Neto da Rocha M, Berceanu A, Nicod C, Haderbache R, Roussel X, Desbrosses Y, Daguindau E, et al. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. J Immunother Cancer. 2022;10(7). https://doi.org/10.1136/jitc-2021-004222.

Li Z, Deng M, Huang F, Jin C, Sun S, Chen H, Liu X, He L, Sadek AH, Zhang CC. LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cell Mol Immunol. 2020;17(3):272–82. https://doi.org/10.1038/s41423-019-0321-2.

Article  CAS  PubMed  Google Scholar 

Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562(7728):605–9. https://doi.org/10.1038/s41586-018-0615-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

John S, Chen H, Deng M, Gui X, Wu G, Chen W, Li Z, Zhang N, An Z, Zhang CC. A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol Ther. 2018;26(10):2487–95. https://doi.org/10.1016/j.ymthe.2018.08.001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lemoine J, Ruella M, Houot R. Born to survive: how cancer cells resist CAR T cell therapy. J Hematol Oncol. 2021;14(1):199. https://doi.org/10.1186/s13045-021-01209-9.

Article  PubMed  PubMed Central  Google Scholar 

Daver N, Alotaibi AS, Bücklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35(7):1843–63. https://doi.org/10.1038/s41375-021-01253-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie B, Li Z, Zhou J, Wang W. Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies. Cancers (Basel) 2022;14(13). https://doi.org/10.3390/cancers14133230.

Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D, Guo T, Kou H, Liu L, Tang L, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021;14(1):161. https://doi.org/10.1186/s13045-021-01170-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Yang Y, Hong R, Zhao H, Wei G, Wu W, Xu H, Cui J, Zhang Y, Chang AH, et al. A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J. 2020;10(10):105. https://doi.org/10.1038/s41408-020-00371-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, Han X, Ti D, Dai H, Wang C, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood. 2020;136(14):1632–44. https://doi.org/10.1182/blood.2020005278.

Article  PubMed  PubMed Central  Google Scholar 

Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26(10):1569–75. https://doi.org/10.1038/s41591-020-1081-3.

Article  CAS  PubMed  Google Scholar 

Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):30. https://doi.org/10.1186/s13045-020-00856-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu F, Cao Y, Pinz K, Ma Y, Wada M, Chen K, Ma G, Shen J, Tse CO, Su Y. First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood. 2018;132:901.

Article  Google Scholar 

Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. 2020;34(3):682–96. https://doi.org/10.1038/s41375-019-0694-3.

Article  PubMed  Google Scholar 

Li KX, Wu HY, Pan WY, Guo MQ, Qiu DZ, He YJ, Li YH, Yang DH, Huang YX. A novel approach for relapsed/refractory FLT3(mut+) acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib. Mol Cancer. 2022;21(1):66. https://doi.org/10.1186/s12943-022-01541-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673–83. https://doi.org/10.1056/NEJMoa1106152.

Article  PubMed  PubMed Central  Google Scholar 

Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E, Certoux JM, Robinet E, Saas P, Petracca B, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood. 2001;97(1):63–72. https://doi.org/10.1182/blood.v97.1.63.

Article  CAS  PubMed  Google Scholar 

Agliardi G, Liuzzi AR, Hotblack A, De Feo D, Núñez N, Stowe CL, Friebel E, Nannini F, Rindlisbacher L, Roberts TA, et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun. 2021;12(1):444. https://doi.org/10.1038/s41467-020-20599-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun. 2019;10(1):244. https://doi.org/10.1038/s41467-018-08263-x.